Lung Cancer Management: where are we in 2017?
Giorgio Scagliotti 1, Paolo Bironzo 1, Antoni Rosell 2
1 Department of Clinical and Biological Sciences, S. Luigi Gonzaga Hospital, University of Torino, Orbassano, Torino, Italy; 2 Respiratory Medicine Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, CIBERES, IDIBELL, Barcelona, Spain
*Correspondence: Antoni Rosell, Email not available
Abstract
Lung cancer remains the most common cancer and most common cause of death from cancer worldwide. Continuous advancements are taking place in this field. The year 2016 has brought many progresses; especially relevant are the new TNM Classification of Malignant Tumours (TNM) classification and the growing number of genomically-defined subpopulations in the road to developing personalized therapies. The state of the art in the management of lung cancer in 2016 is presented here.
